Most conazole drugs require hepatic monitoring and even discontinuation of therapy if liver enzymes increase above normal limits in response to systemic therapy. Elevated ALT above baseline requires interruption of therapy due to the risk of drug-induced hepatitis. Patients may resume treatment when the liver function returns to baseline.